阿斯利康提议，按124美元/股现金收购Rhythm Pharma。（华尔街日报）
阿斯利康提议，按124美元/股现金收购Rhythm Pharma。（华尔街日报）
AI 解读排队中
该事件正在分析队列中，通常 40 秒内完成。刷新页面即可查看。
同类事件
11-04 23:07
Analysis: The Democrats have one chance to extract concessions from Trump. Marke
风险规避
11-05 06:54
Qualcomm stock drops 6% on weak earnings forecast as memory shortage weighs on s
风险规避
11-05 05:55
Figma sinks after earnings beat as company prioritizes long-term growth with AI
风险规避
11-05 05:40
CVS to split off drugstore business in major breakup of healthcare giant; shares
方向中性
11-05 05:37
Snap shares fall over 10% on third-quarter revenue miss
风险规避
11-05 05:22
Qualcomm stock drops 5% on weak earnings forecast as memory shortage weighs on s
风险规避
发布时间：2026-11-05 05:01:41 · 数据来源：wallstcn · 本文由程序自动生成并经模型解读，可能存在误差，请以原始信息为准。